vitamin K2

Vitamin K2 is a form of the fat‑soluble vitamin K family, distinct from vitamin K1 (phylloquinone) in its structure, sources, and functions in the human body. Vitamin K refers to a group of related compounds sharing a 2‑methyl‑1,4‑naphthoquinone core. Within this family, menaquinones (collectively known as vitamin K2) vary in side chain length (e.g., MK‑4 through MK‑13) and are found predominantly in animal products and fermented foods or produced by bacteria in the gut. While vitamin K1 is abundant in green leafy vegetables, K2 compounds are less common in the typical Western diet and have distinct physiological roles, particularly in bone and cardiovascular health. The most studied menaquinones in humans include MK‑4 and MK‑7. MK‑4 is found in animal tissues and tissues can convert some K1 to MK‑4, while MK‑7 is abundant in fermented foods like natto and tends to stay in circulation longer. As a fat‑soluble vitamin, vitamin K2 is absorbed with dietary fats in the small intestine and transported in chylomicrons, entering circulation where it participates in activating proteins that regulate calcium homeostasis and coagulation. Vitamin K2’s role extends beyond hepatic coagulation functions to extrahepatic tissues such as bone and vasculature, where it activates osteocalcin and matrix Gla‑protein (MGP), crucial for bone mineralization and preventing pathologic arterial calcification. Although the total dietary recommendations for vitamin K encompass both K1 and K2, research increasingly emphasizes the unique contributions of K2, especially menaquinones with longer side chains like MK‑7, in tissue‑specific metabolic processes.

Vitamin K2 serves critical roles in human physiology beyond its classic function in blood clotting. As a cofactor for the enzyme gamma‑glutamyl carboxylase, K2 activates vitamin K‑dependent proteins by enabling the carboxylation of glutamic acid residues, which then bind calcium. In bone tissue, this activation governs osteocalcin, a noncollagenous protein synthesized by osteoblasts that incorporates calcium into the bone matrix. Adequate activation of osteocalcin is linked with improved bone mineral density and reduced fracture risk in observational studies of older adults and postmenopausal women. Beyond skeletal effects, K2 activates matrix Gla‑protein (MGP) in vascular smooth muscle and cartilage. MGP binds calcium and inhibits deposition in soft tissues and arteries, mitigating vascular calcification, a risk factor for hypertension and coronary artery disease. Epidemiological data from large cohort studies indicate that higher dietary intake of K2 is associated with lower incidence of severe aortic calcification and coronary heart disease, suggesting a cardiovascular protective effect. While causality in randomized controlled trials remains under study, mechanistic evidence supports K2’s involvement in calcium homeostasis and arterial flexibility. Vitamin K2 also contributes to the synthesis of clotting factors II, VII, IX, and X and regulatory proteins C and S, making it essential for normal hemostasis. Severe deficiency can lead to prolonged prothrombin time and increased bleeding risk if K2 is insufficient to activate hepatic clotting factors. Emerging research explores potential roles for K2 in extraskeletal tissues, including modulation of inflammation and cellular processes that may influence cancer cell proliferation; however, these outcomes require further validation in human trials. Overall, the consensus in clinical nutrition highlights vitamin K2’s multi‑system contributions to calcium metabolism, bone integrity, and vascular health.

The Dietary Reference Intakes established by the Food and Nutrition Board at the Institute of Medicine provide Adequate Intake (AI) levels for total vitamin K (including K1 and K2) rather than specific Recommended Dietary Allowances for individual menaquinones. For adults aged 19 years and older, the AI is set at 120 mcg per day for men and 90 mcg per day for women, including during pregnancy and lactation. These intake values reflect the amount needed to maintain normal blood coagulation and bone health in healthy individuals. Adequate intake during infancy and childhood varies with age, from 2.0–2.5 mcg for infants to 75 mcg for teens. Although specific K2 intake recommendations are not separated from total K, experts recognize that a balanced intake of both K1 and K2 contributes to meeting total AI. Factors affecting vitamin K needs include dietary fat intake, since K2 absorption is enhanced with dietary fats, and gastrointestinal health, as malabsorption disorders can reduce uptake of fat‑soluble vitamins. Because K2 forms differ in half‑life—MK‑7 has a longer circulating time than MK‑4—diets containing fermented foods like natto may sustain vitamin K2 status more effectively than diets reliant solely on animal sources. Individuals with conditions that increase bone turnover or cardiovascular risk might require higher vitamin K2 status for optimal metabolic effects, though there are no official higher recommendations. Clinical judgment often considers blood markers of undercarboxylated osteocalcin to assess adequacy in bone health settings, but these markers are not routinely used for general screening. Regardless, aiming for a variety of vitamin K sources, including K2‑rich foods, supports meeting total vitamin K AI and its associated health benefits.

Vitamin K2 deficiency is uncommon in the general population with sufficient dietary intake and normal fat absorption, given the body’s ability to recycle vitamin K and gut bacterial synthesis. However, deficiency states arise in specific clinical contexts. Early deficiency signs relate to impaired activation of vitamin K‑dependent proteins, particularly clotting factors. This manifests as easy bruising, petechiae, hematomas, oozing at surgical or puncture sites, and prolonged prothrombin time on laboratory tests. Severe deficiency can cause hemorrhagic disease in newborns, which is why newborns routinely receive vitamin K at birth to prevent bleeding complications. In adults, deficiency may be precipitated by malabsorption disorders such as cystic fibrosis, celiac disease, inflammatory bowel disease, and bariatric surgery, all of which impair fat and fat‑soluble vitamin absorption. Prolonged antibiotic use can diminish gut bacteria that produce K2, potentially lowering circulating menaquinones, though the clinical significance varies. Chronic warfarin or other vitamin K antagonist therapy effectively induces a functional deficiency state by blocking vitamin K recycling and interfering with clotting factor activation. Less obvious signs of long‑term suboptimal K2 status may involve increased arterial calcification and reduced bone mineral density, but these associations are subtle and not diagnostic on their own. The most definitive clinical indicator of vitamin K deficiency remains prolonged clotting times, measurable by prothrombin time or International Normalized Ratio (INR), especially when other causes are excluded. Because menaquinone levels in plasma are not routinely measured and reference ranges are not well established, clinicians focus on clinical presentation, risk factors for deficiency, and response to supplementation when diagnosing insufficiency.

Vitamin K2 is found predominantly in fermented foods and animal products due to bacterial synthesis of menaquinones or conversion of K1 to MK‑4 in animal tissues. Quantifying precise amounts is challenging because food composition varies with animal diet and fermentation conditions, but data from nutrition analyses identify several high‑K2 foods. Natto, a fermented soy product, stands out as the richest source of vitamin K2, particularly MK‑7 forms, with concentrations exceeding 800–1000 mcg per 100 grams. Fermented cheeses like Jarlsberg, Gouda, and certain blue cheeses provide moderate amounts of menaquinones (e.g., 70+ mcg per 100 g in Jarlsberg). Organ meats, especially goose and chicken liver, are rich in MK‑4, reflecting high menaquinone content per serving. Eggs, especially yolks from pastured hens, contribute small but meaningful amounts of K2. Other animal foods such as chicken (dark meat), pork products, and dairy fats provide additional vitamin K2, though at lower concentrations than fermented or organ sources. Food matrix and preparation influence bioavailability; for example, dietary fat enhances absorption of fat‑soluble K2. Traditional Western diets often underdeliver K2 relative to K1, leading some individuals to rely on specific foods like natto or high‑menquinone cheeses to boost intake. Including a variety of these sources in meals supports adequate total vitamin K and harnesses the unique roles of menaquinones in calcium regulation and metabolic health.

Vitamin K2’s absorption is linked to fat digestion; because it is fat‑soluble, dietary fat and bile acids are essential for micelle formation in the small intestine and uptake into enterocytes. Long‑chain menaquinones like MK‑7 have a longer half‑life in circulation compared to short‑chain forms like MK‑4, which may translate to more sustained bioavailability. Co‑consumption of dietary fat enhances absorption, and fat malabsorption conditions (e.g., cholestatic liver disease, pancreatic insufficiency) can significantly reduce vitamin K2 uptake. Plant‑derived K1 is less bioavailable than K2 due to tight binding in chloroplast membranes, whereas K2 in animal and fermented sources is more readily incorporated into micelles. The gut microbiome also produces K2, though the extent to which this contributes to overall status in humans remains unclear. Factors such as aging, certain medications (e.g., bile acid sequestrants), and gastrointestinal surgeries can reduce absorption efficiency. Eating K2‑rich foods with meals that contain healthy fats maximizes uptake and supports tissue distribution.

Supplementation may benefit individuals with restricted diets (e.g., strict vegan excluding natto), malabsorption disorders, or those at risk for osteoporosis or cardiovascular disease. Clinical trials exploring menaquinone supplementation, particularly MK‑7, show improvements in markers of bone health and reductions in arterial stiffness, but recommendations should be personalized. Supplements vary in form (MK‑4 vs. MK‑7), dosage, and quality; MK‑7 has a longer half‑life and may support sustained plasma levels. Healthcare providers often advise third‑party tested products and careful integration when on medications like anticoagulants. While the general population typically meets total vitamin K needs through diet, targeted supplementation under medical guidance can address specific risk factors.

Vitamin K2 has no established Tolerable Upper Intake Level due to low toxicity; excessive intakes do not lead to adverse outcomes in healthy individuals. High doses used in research (tens of milligrams) have not demonstrated toxicity. However, supplementation should be monitored in people on anticoagulant medications, as abrupt changes in intake can affect clotting control.

Vitamin K2 interacts with certain medications, most notably warfarin and other vitamin K antagonists, which rely on stable vitamin K metabolism for therapeutic effect. Increasing or decreasing K2 intake can reduce warfarin’s anticoagulant effect and alter INR, necessitating close monitoring of clotting parameters. Other drugs that may affect K2 status include bile acid sequestrants (e.g., cholestyramine, colestipol, colesevelam) and orlistat, which impair fat absorption and thus fat‑soluble vitamin uptake. Prolonged use of broad‑spectrum antibiotics can reduce gut bacteria that synthesize menaquinones, potentially lowering K2 levels. Patients on these medications should consult clinicians before adjusting diet or supplements.

Common Forms: MK‑4, MK‑7, combo K1+K2

Typical Doses: 50–360 mcg/day in supplements

When to Take: with meals containing fat

Best Form: MK‑7 due to longer half‑life

⚠️ Interactions: warfarin, cholestyramine, colestipol, colesevelam, orlistat